Page 1

REVELATION BIOSCIENCES Revelation Biosciences , Inc. Announces Financial Results For the Three and Six Months Ended June 30 , 2026 Exhibit 99.1 SAN DIEGO - August 6 , 2026 Revelation Biosciences , Inc. ( NASDAQ : REVB ) ( the “ Company ” or “ Revelation ” ) , a clinical - stage life sciences company developing innovative solutions to treat acute and chronic disease , today reported its financial results for the three and six months ended June 30 , 2026 . Corporate Highlights • Announced formation of an Acute Kidney Injury Advisory Board for the upcoming Phase 2/3 AKI clinical trial and subsequent expansion of the AKI Advisory Board Continued progress on Phase 2/3 clinical study start up activities Released results of an independent market assessment that showed a potential $ 94 billion total addressable market for Gemini " Start - up activities for our pivotal clinical study of Gemini in acute kidney injury patients continue to progress , " said James Rolke , Chief Executive Officer of Revelation . “ Our focus remains on starting enrollment by year - end , for the benefit of those patients and , ultimately , to deliver value for our shareholders . " Results of Operations As of June 30 , 2026 , Revelation had $ 11.5 million in cash and cash equivalents , compared to $ 10.7 million as of December 31 , 2025. The increase in cash and cash equivalents was primarily due to net cash proceeds from the January 2026 warrant inducement , offset by cash used for operating activities . Based on current operating plans and projections , Revelation believes its current cash and cash equivalents are sufficient to fund operations through the first quarter of 2027 . Net cash used for operating activities for the three months ended June 30 , 2026 was $ 2.6 million compared to net cash used for operating activities of $ 1.9 million for the same period in 2025. Net loss for the three months ended June 30 , 2026 was $ 3.3 million , or $ 0.87 basic and diluted net loss per share compared to net loss of $ 2.4 million , or $ 28.04 basic and diluted net loss per share for the three months ended June 30 , 2025. Net loss for the six months ended June 30 , 2026 was $ 6.3 million , or $ 3.41 basic and diluted net loss per share compared to net loss of $ 4.5 million , or $ 54.39 basic and diluted net loss per share for the six months ended June 30 , 2025 .